Although trastuzumab, a recombinant humanized anti-ErbB2 antibody, is widely used in the treatment of breast cancer, neither its mechanism of action, nor the factors leading to resistance are fully understood. We have previously shown that antibody-dependent cellular 
Introduction
Overexpression of ErbB2 has been unquestionably linked to adverse prognosis in breast cancer. 1 ErbB2 heterodimerizes with other members of the ErbB family of receptor tyrosine kinases (RTK) leading to enhanced ligand binding affinity, protection from lysosomal degradation and diversified signaling. 2 ErbB2 is viewed as an non-autonomous, ligand-less, positive regulator of ErbB signaling, 2 but its participation in non-ErbB protein-mediated signaling is attracting more and more interest as well. Among these, β-integrins, 3 MUC-4 4 and CD44 5 are probably the best known candidates whose roles in cancer progression are well documented. 3, 6, 7 ErbB2 is embedded into this network of signaling and accessory molecules and by its promiscuous association profile it promotes cancer progression. 8 CD44 is recognized as the major hyaluronan receptor having several, alternatively spliced isoforms varying in their physiological function. 9 Binding of hyaluronan activates CD44-mediated signal transduction pathways via interactions between CD44, Grb2, Vav2 and ErbB2. 10 CD44 is involved in the direct regulation of ErbB2 11 and multiple other RTKs. 12 It has been suggested that ligation of CD44 by endogenous hyaluronan leads to the activation of the phosphatidylinositol 3-kinase (PI3K)-Akt survival pathway, 13 and that displacement of endogenous hyaluronan by exogenous hyaluronan oligosaccharides disrupts the activation.
12
CD44-mediated cytoskeletal rearrangements have been observed 6 implying the involvement of CD44 in cellular adhesion, migration and invasion. 14 CD44 is almost absent in normal human breast epithelial cells, emerges in benign and premalignant lesions, and is upregulated in carcinomas. 15 However, a recent study suggested that CD44 opposes rather than promotes the spreading of breast carcinoma in mice. 16 While the role of CD44 in breast cancer progression in vivo is not completely settled, the accumulation of hyaluronan around malignant cells or in adjacent stroma has been unambiguously shown to be an indicator of poor prognosis in breast cancer. 17 In line with the findings on human tumours, hyaluronan synthesis facilitates the invasive growth of grafted tumour cells in vivo, 18 and blocking hyaluronan interactions with its receptors, using soluble CD44 or hyaluronan oligomers, inhibits tumour cell growth in experimental animals. 19 Besides creating signals to prevent apoptosis 13 , hyaluronan is required for activation of the ErbB2-ErbB3 receptor leading to the formation of cardiac valves. 20 Thus, there is mounting evidence that ErbB2, CD44 and hyaluronan are connected both in physiological signaling as well as cancer pathogenesis through mechanisms largely unknown at present. 5, 11 Being a membrane protein and a key member of survival and proliferation signaling pathways ErbB2 is the target of receptor-oriented antibody therapy. 21 Trastuzumab (Herceptin), a humanized monoclonal anti-ErbB2 antibody, induces objective clinical responses in 40% of patients as a single agent given as first-line treatment of ErbB2-overexpressing metastatic breast cancer. 22 Although combination of trastuzumab with conventional chemotherapy increases response rates dramatically, the development of resistance seems currently inevitable. 23 Direct action of trastuzumab on ErbB2 (e.g. ErbB2
down-regulation, inactivation of Akt, inhibition of metalloprotease-mediated shedding) 24 and antibody-dependent cellular cytotoxicity (ADCC) 25, 26 In the current paper we investigated JIMT-1, a cell line showing in vitro resistance to trastuzumab, 30 and found a high level of CD44 overexpression. We showed previously that the in vivo trastuzumab resistance of the cell line is partial, and development of complete trastuzumab resistance takes 5-10 weeks. 26 We suggested that masking of ErbB2 may be the culprit. 4 Given the suggested association of CD44 with ErbB2 11 we asked whether CD44 plays any significant role in the survival of JIMT-1 during trastuzumab therapy. Using siRNA-mediated suppression of CD44 expression we showed that CD44 is necessary for trastuzumab-induced internalization of ErbB2 and for the survival of JIMT-1 cells in vitro. 4-methylumbelliferone (4-MU), a hyaluronan synthase inhibitor, has been shown to increase the efficiency of chemotherapy. 31 We reasoned that hyaluronan may play a role in masking of cell surface ErbB2. 32 We and ErbB2 in JIMT-1 and SKBR-3, respectively, show that these molecules are associated at the molecular level as well (Fig.1B) , since FRET values above 5% are considered to imply significant association. 40 The above biophysical data demonstrating association between ErbB2 and CD44 in JIMT-1 cells were reinforced by molecular biological methods. ErbB2 co-immunoprecipitated with CD44 (Fig. 1D , left panel), and its tyrosine phosphorylation was increased by large molecular weight hyaluronan, whereas hyaluronan decasaccharide inhibited ErbB2 tyrosine phosphorylation (Fig. 1D , middle panel). Neither slow, nor large molecular weight hyaluronan modified the activation state of ErbB1 (Fig. 1D , right panel).
Materials and Methods

Cells
CD44 expression correlates with trastuzumab internalization in JIMT-1 xenografts. In order to study the possible role of CD44 overexpression in trastuzumab resistance sevenweek old female SCID mice were inoculated by JIMT-1 cells with a single subcutaneous injection. Mice received trastuzumab or physiologic saline weekly starting immediately after tumour injection. Mice were treated with trastuzumab for 9 weeks, then by physiologic saline for another 6 weeks before sacrificing. Tumour sections were triple-stained against ErbB2, trastuzumab and CD44. The watershed algorithm was used to segment the images.
The seeds for the watershed algorithm were placed inside cells positive for CD44 and ErbB2.
Since mouse stromal cells express neither CD44 nor ErbB2, this approach ensured that the analysis was restricted to JIMT-1 cells. We observed a lack of tight correlation between trastuzumab binding and ErbB2 expression in these mice whose trastuzumab therapy had been suspended for 6 weeks (Fig. 2B,D) . The trastuzumab/ErbB2 ratio was inversely correlated with CD44 expression, i.e. cells in which the relative binding of trastuzumab to
ErbB2 was low displayed high CD44 expression (Fig. 2D,E) . The lack of strict correlation between trastuzumab binding and ErbB2 expression could be caused by local heterogeneities in trastuzumab binding or internalization. We excluded the role of trastuzumab binding by investigating tumour sections from mice sacrificed immediately after 15 weeks of trastuzumab treatment and showing a tight correlation between trastuzumab binding and ErbB2 expression (Fig. 2F) . Unfortunately, direct quantitation of trastuzumab internalization by measuring fluorescence intensity inside cells was not possible due to the low signal-tonoise ratio. Therefore, we used an alternative approach by analyzing the correlation between CD44 and ErbB2 expressions before, during and after trastuzumab treatment, and found that they show a positive correlation in control mice (Fig. 2G ) and in mice in which trastuzumab treatment has been stopped (Fig. 2I) . Strikingly, CD44 and ErbB2 expression levels were inversely correlated with each other during trastuzumab treatment (Fig. 2H) supported by the lack of effect of an irrelevant siRNA on CD44 expression, and the lack of CD44 siRNA-induced suppression of the expression of an irrelevant protein (Fig. 3A) .
Quantitative flow cytometric analysis confirmed that CD44 siRNAs inhibited trastuzumab internalization by ~50% (Fig. 3B ).
4-methylumbelliferone (4-MU) synergizes with trastuzumab in inhibiting the growth of
JIMT-1 xenografts. We showed that CD44 plays a role in trastuzumab internalization both in vivo and in vitro. However, the contribution of trastuzumab-mediated ErbB2 internalization to the mechanism of action of the antibody has been repeatedly questioned 41, 42 . Therefore, we directly tested whether the CD44-hyaluronan pathway can influence the (Fig. 4A ). 4-MU did not have any effect on tumour growth on its own (Fig. 4A) , although it reduced the amount of hyaluronan in JIMT-1 tumour tissue by ~40% (Fig. 4B ). In addition, CD44 expression was increased by 4-MU probably due to its decreased hyaluronan-mediated down-regulation. 43 The increased CD44 level of trastuzumab-treated cells is probably the consequence of reduced CD44 shedding in the presence of trastuzumab (our unpublished observation). 4-MU downregulated ErbB2 to the same extent as trastuzumab. We attribute this finding to the fact that 4-MU increased the CD44 level of cells which was shown to correlate with increased ErbB2 internalization (Fig. 2) . Not only did 4-MU synergize with trastuzumab in slowing tumour growth, but it also enhanced trastuzumab-mediated down-regulation of ErbB2 (Fig. 4B ). Since we assumed that 4-MU may unmask the trastuzumab-binding epitope on ErbB2, it was necessary to show that hyaluronan colocalized with the plasma membrane. By staining tumour sections for hyaluronan and CD44 we demonstrated that hyaluronan is present near the cell membrane, although it is also found in high density in areas which seem to be interstitial tissue (Fig. 5A-C ). Next, we determined the trastuzumab/ErbB2 ratio in control and trastuzumab+4-MUtreated tumour samples and observed an obvious increase in the relative binding of trastuzumab to ErbB2 upon 4-MU treatment ( Fig. 5D-E) . Quantitative analysis of the images showed a shift on the trastuzumab-ErbB2 contour plot towards higher trastuzumab binding upon 4-MU treatment (Fig. 5F ). Next, we tested the effect of in vitro 4-MU treatment on trastuzumab binding. JIMT-1 cells were treated with 4-MU for 48 hours, and subsequently labeled with AlexaFluor488-trastuzumab and AlexaFluor647-2C4. We found that 4-MU treatment enhanced the amount of bound trastuzumab relative to the intensity of ErbB2 (Fig.   5G ). ErbB2 was not downregulated by trastuzumab in Fig. 5G , since cells were labeled with trastuzumab for 30 min on ice, as opposed to Fig. 5F , where mice were treated with the antibody for several weeks. The trastuzumab epitope is masking sensitive 4 due to its membrane proximal position. 44 Since the ErbB2-76.5 and 2C4 antibodies recognize an epitope distinct from and less masking sensitive than that of trastuzumab (our unpublished observation), we assumed that their intensities represented the total amount of ErbB2. The 4-MU-induced changes in the trastuzumab/ErbB2 ratio present convincing evidence for the in vitro and in vivo masking effect of hyaluronan on the trastuzumab binding epitope.
CD44 is essential for the proliferation of JIMT-1 cells in vitro. Since CD44 is overexpressed by JIMT-1 cells and it is involved in regulating trastuzumab-mediated ErbB2
internalization, we investigated whether the inhibition of CD44 expression alters the effect of trastuzumab in vitro. As previously shown JIMT-1 cells were resistant to trastuzumab in vitro, 30 but their proliferation was inhibited by siRNA-mediated suppression of CD44 expression (Fig. 6 ). However, no additive effect between trastuzumab and CD44 siRNA was detected. SKBR-3 cells responded to trastuzumab treatment, but in agreement with their low CD44 expression failed to show any response to siRNA-mediated suppression of CD44 expression (Fig. 6 ).
Discussion
CD44 is widely recognized as a key factor in lymphocyte homing and cancer progression. 14 It has been shown to enhance the signaling potency of several growth factor receptors in general 12 and to interact with ErbB2 in particular, 5, 10, 11 siRNA-mediated suppression of CD44 expression inhibited trastuzumab internalization in vitro (Fig. 3) . Since CD44 is known to be linked to actin 6 and endocytosis and post-endocytic sorting are coupled to the cytoskeleton in several ways 46 , it is possible that inhibition of the expression of CD44 interferes with the endocytic process. Alternatively, since CD44 plays a permissive role in the activation of ErbB2, 11 elimination of this constitutive regulator of ErbB2 may inhibit trastuzumab internalization. The role of CD44 in trastuzumab internalization and down-regulation was confirmed by studying the correlation between trastuzumab binding, ErbB2 and CD44 expressions in JIMT-1 xenografts. In control mice the correlation between CD44 and ErbB2 expressions was positive (Fig. 2G) , which was converted to an inverse correlation by trastuzumab treatment (Fig. 2H) . ErbB2 is downregulated by trastuzumab (Fig. 4B) , and we assume that this process is more efficient in cells with high CD44 expression, therefore CD44 high cells will end up being low expressers of ErbB2 upon trastuzumab treatment. The fact that CD44 expression correlates with trastuzumab-induced ErbB2 internalization in vivo agrees with our in vitro data showing decreased internalization of trastuzumab after knocking down CD44 expression (Fig. 3) . We showed previously that after stopping trastuzumab injections ErbB2 expression returns to a level observed in untreated animals. 26 While trastuzumab is cleared from the circulation resynthesis of ErbB2 takes place primarily in cells in which ErbB2 expression was downregulated, i.e. the CD44 high subpopulation. Trastuzumab will probably not bind to ErbB2 synthesized 6 weeks after stopping trastuzumab treatment, since the antibody is eliminated from the circulation with a half-life of ~25 days, 47 and its concentration is probably lower in the tumour stroma than in the circulation. Even if trastuzumab had bound to newly synthesized ErbB2 six weeks after stopping trastuzumab treatment, we would not have observed substantial cell-to-cell variation in the binding of trastuzumab to ErbB2 (Fig. 2D) .
Therefore, CD44 high cells in which ErbB2 has been down-regulated will display newly synthesized ErbB2 without trastuzumab on their surface, i.e. their trastuzumab/ErbB2 ratio will be lower than that of CD44 low cells in which ErbB2 has been down-regulated less efficiently (Fig. 2D,E) . The trastuzumab/ErbB2 ratio of CD44 low cells was high because they still displayed ErbB2 in their membrane to which trastuzumab had bound during trastuzumab treatment. Although the role of trastuzumab-induced ErbB2 down-regulation in the therapeutic action of the antibody has been questioned 41, 42 , the debate is not yet settled. The finding that CD44 is involved in ErbB2 internalization and down-regulation shows that it influences the distribution of ErbB2 among different cellular compartments, which may alter the therapeutic effects of trastuzumab. Additionally, if trastuzumab is used to target ErbB2 overexpressing cells with radioactive isotopes or chemotherapeutics, entry of the antibodycoupled drug into the cell will be affected by the level of CD44 expression.
In addition to its involvement in regulating endocytosis of ErbB2, CD44 can modify trastuzumab-induced effects by masking ErbB2 by its bulky ligand, hyaluronan. We have previously described masking of ErbB2 by MUC-4, a cell surface mucin, also expressed by the JIMT-1 cell line. 4 In this paper we established that hyaluronan also masks the trastuzumab binding epitope by showing that hyaluronan was present in the immediate vicinity of JIMT-1 cells (Fig. 5A-C) , and 4-MU, an inhibitor of hyaluronan synthase, 33 substantially reduced its concentration accompanied by increased trastuzumab binding (Fig.   4B , 5F). The enhanced expression level of CD44 in 4-MU-treated xenografts (Fig. 4B) is probably attributable to lower rate of hyaluronan-induced CD44 endocytosis. 43 Since CD44
seems to increase ErbB2 down-regulation (Fig. 3B) , the higher CD44 level in 4-MU-treated samples may lead to the lower level of ErbB2 expression observed in these animals (Fig. 4B ).
Decreased concentration of hyaluronan around JIMT-1 cells resulted in increased binding of trastuzumab to (Fig. 5D-F ) and more efficient down-regulation of ErbB2 (Fig. 4B ). More importantly, the enhanced binding of trastuzumab to ErbB2 induced by 4-MU increased the efficiency of trastuzumab therapy in vivo (Fig. 4A) . It has been shown previously that hyaluronan-cell interactions are important for cancer cell survival and metastasis. 48 The fact that 4-MU alone did not alter the rate of JIMT-1 tumour growth compared to saline-treated animals suggests that either hyaluronan is not necessary for the survival of JIMT-1 cells or the extent of suppression of hyaluronan synthesis was not sufficient for evoking an effect on tumour growth. Nevertheless, the suppression of hyaluronan synthesis induced by 4-MU treatment was large enough to decrease masking of ErbB2 and increase the binding and therapeutic effect of trastuzumab. It was reported that 4-MU inhibited the proliferation of keratinocytes more strongly than expected based on the level of inhibition of hyaluronan synthesis. 49 This phenomenon was attributed to direct antiproliferative effects of 4-MU unrelated to hyaluronan synthesis. The fact that 4-MU as a single agent was ineffective in our study argues against this possibility in JIMT-1 cells. Although 4-MU specifically inhibits the synthesis of hyaluronan, 33 we cannot rule out the possibility that the production of other glycosaminoglycans was also suppressed. However, the observed increase in trastuzumab binding after 4-MU treatment is a solid evidence for masking whatever molecules are behind it.
The extremely high overexpression of CD44 by JIMT-1 cells (~2. siRNA and trastuzumab, since the former inhibits the internalization of the latter (Fig. 3B) .
Alternatively, the CD44-hyaluronan pathway involved in in vivo trastuzumab resistance may have very limited role in the in vitro resistance of JIMT-1. 4 It is also possible that although CD44 is involved in trastuzumab internalization, it is unrelated to trastuzumab resistance due to the dubious role of ErbB2 internalization and downregulation in trastuzumab resistance. 41 In conclusion, our results point to a role of CD44 in regulating trastuzumab internalization and masking ErbB2 by serving as an anchor of the hyaluronan meshwork.
These findings warrant further investigation of the correlation between trastuzumab resistance, masking of ErbB2, CD44 and hyaluronan expressions, and a deeper look at how CD44-expressing breast cancer stem cells are affected by trastuzumab therapy. weeks. In another group mice were sacrificed 6 weeks after a 9-week long trastuzumab treatment was stopped (I), and the correlation between CD44 and ErbB2 expression levels was analyzed in the three samples. +trast. -trast.
